The Health Minister's denial of an insulin shortage crisis appears is downplaying a serious issue. Reports from sources such as health portal Code Blue and DAP’s own MP Dr. Kelvin Yii reveal a widespread shortage. The Ministry’s claim that only one supplier faces issues fails to address broader concerns about insulin supply across various states. The reliance on insulin analogues and oral medications, while helpful, is only a temporary fix. The recurring nature of this problem highlights significant flaws in the government's management of diabetic treatments. We need to take immediate action to protect diabetic patients.

Immediate actions are essential. The government should, at the very least, acknowledge the crisis and assess the insulin supply situation to identify and address stock level and distribution issues. Additionally, they should engage in solutions that includes expanding the supplier network by engaging additional local and international suppliers and resolving production issues with existing suppliers. Improving distribution and inventory management can ensure that insulin reaches all affected areas. Increasing the use of insulin analogues and oral medications can help mitigate the impact of the shortage temporarily.

Ensuring a continuous, undisrupted supply of insulin requires revising procurement policies, developing contingency plans, and investing in production and logistics. Strengthening collaboration with stakeholders and enhancing regulatory oversight will help prevent shortages. Educating patients and providers on managing diabetes during such periods are also crucial.

Insulin shortages can lead to severe complications like hyperglycemia, hypoglycemia, and life-threatening conditions such as diabetic ketoacidosis (DKA). Vulnerable populations, for example those in rural areas, are particularly at risk. Interruptions in insulin therapy can result in unstable blood sugar levels and deteriorate long-term health management. Additionally, the stress and anxiety caused by such shortages can negatively impact patients' mental health.

In Malaysia, the prevalence of diabetes has risen from 11.2% in 2011 to 18.3% in 2019. With nearly 1 in 5 adults in Malaysia affected by diabetes, investing in local insulin production through enhanced pharmaceutical R&D could be highly beneficial. This long-term strategy would address the growing demand for insulin, reduce reliance on imports, and lower healthcare costs, while improving overall public health and economic self-sufficiency.

Even if it seems that insulin shortages impact only those with medical conditions requiring it, we must not disregard the looming crisis. It is essential to address this issue with equal attention, ensuring that we do not neglect the needs of vulnerable individuals who rely on insulin.

Dr Pamela Yong
MCA Deputy Secretary General
Wanita MCA Sabah Chairperson

27 August 2024